NFKB1 and B-cell chronic lymphocytic leukemia: Inhibition of NF-κB activation has been explored in CLL cells, e.g., with parthenolide-based compounds (targeting IKK activation) and DC-1-192 (inhibiting subunit binding) which induce apoptosis and decrease NF-κB-dependent gene transcription [17,18].